Effect of imeglimin (Twymeeg) on pre-prandial glucose in patient with persisting post-prandial hyperglycemia

As recent topic for oral hypoglycemic agent (OHA), imeglimin (Twymeeg) shows clinical efficacy. Current case is 77-year-old female with type 2 diabetes (T2D) for years. HbA1c increased to 8.4% in Jan, 2023 and then Twymeeg was initiated. She has continued detail measurement of pre-prandial glucose 3 times a day, and these data were analyzed during Dec 2022 to Feb 2023. As a result, HbA1c decreased to 7.9% in 5 weeks, and pre-prandial level has decreased in satisfactory degree. In contrast, she kept intake of certain amount of carbohydrates in 3 meals as usual, and post-prandial hyperglycemia has been stable.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.